Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
The use of cannabis-derived medicines is now allowed in Japan through the amendment of the Cannabis Control Act and the Narcotics and Psychotropics Control Act late last year, but domestic R&D in the arena is still in its infancy. To…
To read the full story
Related Article
- Hemp Cannabinoid Consortium Draws 40 Inquiries from Industry and Academia
August 22, 2025
- Jazz’s Epilepsy Drug Candidate Nearing Submission as Japan Lifts Ban on Cannabis-Derived Meds
December 18, 2024
- Japan Grants Orphan Tag to Cannabidiol, 6 More APIs
June 10, 2024
- Japan Diet Enacts Bill to Lift Ban on Cannabis-Derived Drugs
December 8, 2023
- Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
June 27, 2022
ACADEMIA
- Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
March 3, 2026
- 63% of OB-GYN Clinics Adopt RSV Maternal Vaccine 1 Year after Launch
February 25, 2026
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…